Andrew Evans, MBBS, MD, FRACP

Consultant Neurologist
The Royal Melbourne Hospital, Australia

Poster(s):

• (85) Efficacy and safety of fixed-dose tavapadon, an oral, once-daily, selective D1/D5 dopamine agonist for the treatment of early Parkinson’s disease
  Wednesday, October 29, 2025